Tag Archives: 6MWT

April, 2016

  • 26 April

    FDA Panel Votes Against Sarepta’s Drug to Treat Duchenne Muscular Dystrophy

    CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 25, 2016– Sarepta Therapeutics, Inc.(NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today announced that the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Advisory Committee (PCNSC) met to review the new drug application (NDA) for eteplirsen as a treatment for Duchenne muscular dystrophy amenable to exon 51 …